查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1570848

抗生素抗藥性市場：按類型、作用機制、活性頻譜、藥物類別、給藥途徑、最終用戶、分銷管道 - 2025-2030 年全球預測

Antibiotic Resistance Market by Type, Mechanism of Action, Spectrum of Activity, Drug Class, Route of Administration, End User, Distribution Channel - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 181 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年抗生素抗藥性市場價值為90.2億美元，預計到2024年將達到98.7億美元，複合年成長率為9.40%，到2030年將達到169.3億美元。

抗生素抗藥性是一個重要的公共衛生問題，是指細菌和其他微生物抵抗曾經成功治療感染疾病的藥物作用的能力。這種抗藥性對全球構成重大威脅，影響人類和動物健康，對農業、醫療保健和經濟穩定產生重大影響。解決抗生素抗藥性問題的必要性在於，普通治療可能會變得無效，導致病情延長和死亡率增加。它們的應用範圍廣泛，包括在醫學領域（迫切需要新型抗生素）和在農業領域（政策變化要求負責任地使用）。主要的最終用途部門是醫療保健提供者、製藥公司和監管機構。

主要市場統計
基準年[2023] 90.2億美元
預測年份 [2024] 98.7億美元
預測年份 [2030] 169.3億美元
複合年成長率（%） 9.4%

市場促進因素包括抗藥性感染疾病的增加、政府謹慎使用抗生素的措施以及增加對噬菌體和胜肽等替代治療方法研發的資金。生物技術產業的創新，特別是快速診斷工具和個人化醫療方面的創新，預示著巨大的商機。然而，挑戰包括由於高成本和監管嚴格而導致新抗生素開發速度緩慢等限制。此外，在監管較少的市場中濫用抗生素的可能性以及全球在獲得新治療方法的差異是影響成長的其他因素。

有很多機會可以增強快速診斷技術並開發替代療法，例如益生菌和疫苗，以最大限度地減少濫用並保持抗生素的有效性。對公司的建議包括投資於合作研究和開發以及倡導支持性政策框架以加快藥物核准。創新研究領域，例如利用 CRISPR 開發標靶抗生素，前景尤其光明。市場在技術進步和監管條件的推動下高度活躍，對於那些希望在利用新的科學突破的同時緩解市場狀況的相關人員來說，這是一個緊迫的機會主義領域。

市場動態：揭示快速發展的抗生素抗藥性市場的關鍵市場洞察

供需的動態交互作用正在改變抗生素抗藥性市場。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，以及消費行為及其對製造成本的影響，還可以更清楚地了解其對採購的影響趨勢。

波特的五力：駕馭抗生素抗藥性市場的策略工具

波特的五力框架是理解市場競爭格局的重要工具。波特的五力框架描述了評估公司競爭和探索策略機會的清晰方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解抗生素抗藥性市場的外部影響

外部宏觀環境因素在塑造抗生素抗藥性市場的表現動態發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並幫助他們做出積極主動的決策。

市場佔有率分析 了解抗生素抗藥性市場的競爭格局

對抗生素抗藥性市場的詳細市場佔有率分析可以對供應商績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、細分和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣抗生素抗藥性市場供應商的績效評估

FPNV定位矩陣是評估抗生素抗藥性市場供應商的重要工具。此矩陣允許業務組織根據供應商的商務策略和產品滿意度評估供應商，從而做出符合其目標的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析和建議描繪了抗生素抗藥性市場的成功之路

抗生素抗藥性市場的策略分析對於旨在加強其在全球市場的影響力的公司至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭格局中的挑戰，利用新的商機並取得長期成功。

該報告提供了涵蓋關鍵焦點細分市場的全面市場分析。

1. 市場滲透率：對當前市場環境的詳細回顧。

2. 市場開拓：辨識新興市場的成長機會，評估現有產業的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢視市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，以幫助相關人員做出明智的決策。

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品和地區提供最佳投資機會？

3.塑造市場的關鍵技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 與抗生素抗藥性感染疾病相關的醫療成本上升有助於市場成長
      • 快速診斷檢測的廣泛採用推動了抗生素抗藥性的市場需求
      • 透過加強製藥公司和研究機構之間的合作解決抗生素抗藥性問題
      • 新興市場對抗生素抗藥性解決方案表現出極大的興趣和潛力
    • 抑制因素
      • 監管障礙和核准延遲阻礙了新抗生素的採用
    • 機會
      • 開發針對抗生素抗藥性菌株的新型抗生素，以滿足重要的醫療需求
      • 引進先進的診斷工具來早期發現和管理抗生素抗藥性感染疾病
      • 透過尋找噬菌體和益生菌等替代療法來消除抗生素抗藥性
    • 任務
      • 製藥公司與學術機構在抗生素研究方面缺乏合作
  • 市場區隔分析
  • 波特五力分析
  • PESTLE分析
    • 政治
    • 經濟
    • 社會
    • 科技
    • 法律
    • 環境

第6章抗生素抗藥性市場：依類型

  • 介紹
  • 抗菌產品
  • 抗真菌產品
  • 驅蟲藥
  • 抗病毒產品

第7章抗生素抗藥性市場：按作用機制

  • 介紹
  • 細胞壁合成抑制劑
  • DNA旋轉酶抑制劑
  • 蛋白質合成抑制劑
  • RNA聚合酵素抑制劑

第8章抗生素抗藥性市場：依活動頻譜

  • 介紹
  • 廣效抗生素
  • 窄譜抗生素

第9章抗生素抗藥性市場：依藥物類別

  • 介紹
  • 頭孢菌素
  • Fluoroquinolones
  • 大環內酯
  • 青黴素
  • 四環黴素

第10章抗生素抗藥性市場：依給藥途徑

  • 介紹
  • 靜脈
  • 口服

第11章抗生素抗藥性市場：依最終用戶分類

  • 介紹
  • 診所
  • 居家醫療
  • 醫院

第12章抗生素抗藥性市場：按分銷管道

  • 介紹
  • 醫院藥房
  • 網路藥房
  • 零售藥房

第13章美洲抗生素抗藥性市場

  • 介紹
  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第14章亞太抗生素抗藥性市場

  • 介紹
  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第15章歐洲、中東和非洲抗生素抗藥性市場

  • 介紹
  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第16章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議
Product Code: MRR-535C629188E6

The Antibiotic Resistance Market was valued at USD 9.02 billion in 2023, expected to reach USD 9.87 billion in 2024, and is projected to grow at a CAGR of 9.40%, to USD 16.93 billion by 2030.

Antibiotic resistance, a critical public health issue, refers to the ability of bacteria and other microbes to resist the effects of drugs that once successfully treated infections. This resistance poses a significant threat globally, affecting both human and animal health, with substantial implications for agriculture, healthcare, and economic stability. The necessity for addressing antibiotic resistance lies in its potential to render common treatments ineffective, leading to prolonged illnesses and increased mortality. Applications are vast, including in healthcare, where new classes of antibiotics are urgently needed, and agriculture, where responsible usage is being driven by policy changes. The end-use sectors are largely healthcare providers, pharmaceutical companies, and regulatory bodies.

KEY MARKET STATISTICS
Base Year [2023] USD 9.02 billion
Estimated Year [2024] USD 9.87 billion
Forecast Year [2030] USD 16.93 billion
CAGR (%) 9.4%

Market insights reveal key growth drivers such as the rising incidence of drug-resistant infections, governmental initiatives for prudent antibiotic use, and increased funding for R&D in alternative treatments like bacteriophages and antimicrobial peptides. The biotechnology industry's innovations, particularly in rapid diagnostic tools and personalized medicine, herald substantial opportunities. However, limitations such as the slow pace of new antibiotics development due to high costs and stringent regulations pose challenges. Additional factors affecting growth include the potential misuse of antibiotics in low-regulation markets and disparities in global access to new treatments.

Opportunities abound in enhancing rapid diagnostic technologies, which can minimize misuse and conserve antibiotic efficacy, and developing alternative therapies such as probiotics and vaccines. Recommendations for businesses include investing in collaborative R&D efforts and advocating for supportive policy frameworks to expedite drug approvals. Innovative research areas like harnessing CRISPR-based technologies for targeted antimicrobial therapies are particularly promising. The market is highly dynamic, driven by technological advancements and regulatory landscapes, presenting an urgent yet opportunistic field for stakeholders aiming to mitigate antibiotic resistance while capitalizing on emerging scientific breakthroughs.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Antibiotic Resistance Market

The Antibiotic Resistance Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • High healthcare costs associated with antibiotic-resistant infections contributing to market growth
    • Growing adoption of rapid diagnostic tests for antibiotic resistance driving market demand
    • Increased collaboration between pharmaceutical companies and research institutions to address antibiotic resistance
    • Emerging markets showing significant interest and potential in antibiotic resistance solutions
  • Market Restraints
    • Regulatory hurdles and approval delays hindering the introduction of novel antibiotics
  • Market Opportunities
    • Development of novel antibiotics targeting antibiotic resistant bacterial strains to address critical healthcare needs
    • Implementation of advanced diagnostic tools for early detection and management of antibiotic resistant infections
    • Exploration of alternative therapies such as bacteriophages and probiotics to combat antibiotic resistance
  • Market Challenges
    • Lack of collaboration between pharmaceutical companies and academic institutions in antibiotic research

Porter's Five Forces: A Strategic Tool for Navigating the Antibiotic Resistance Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Antibiotic Resistance Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Antibiotic Resistance Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Antibiotic Resistance Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Antibiotic Resistance Market

A detailed market share analysis in the Antibiotic Resistance Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Antibiotic Resistance Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Antibiotic Resistance Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Antibiotic Resistance Market

A strategic analysis of the Antibiotic Resistance Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Antibiotic Resistance Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Allergan plc, Amgen Inc., AstraZeneca PLC, Aurobindo Pharma Limited, Bayer AG, Bristol-Myers Squibb Company, Cipla Limited, Eli Lilly and Company, Gilead Sciences, Inc., GlaxoSmithKline plc, Johnson & Johnson, Merck & Co., Inc., Novartis AG, Pfizer Inc., Roche Holding AG, Sanofi S.A., Sun Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited, and Teva Pharmaceutical Industries Ltd..

Market Segmentation & Coverage

This research report categorizes the Antibiotic Resistance Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Type, market is studied across Antibacterial Products, Antifungal Products, Antiparasitic Products, and Antiviral Products.
  • Based on Mechanism of Action, market is studied across Cell Wall Synthesis Inhibitors, DNA Gyrase Inhibitors, Protein Synthesis Inhibitors, and RNA Polymerase Inhibitors.
  • Based on Spectrum of Activity, market is studied across Broad-Spectrum Antibiotics and Narrow-Spectrum Antibiotics.
  • Based on Drug Class, market is studied across Cephalosporins, Fluoroquinolones, Macrolides, Penicillins, and Tetracyclines.
  • Based on Route of Administration, market is studied across Intravenous and Oral.
  • Based on End User, market is studied across Clinics, Homecare Settings, and Hospitals.
  • Based on Distribution Channel, market is studied across Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. High healthcare costs associated with antibiotic-resistant infections contributing to market growth
      • 5.1.1.2. Growing adoption of rapid diagnostic tests for antibiotic resistance driving market demand
      • 5.1.1.3. Increased collaboration between pharmaceutical companies and research institutions to address antibiotic resistance
      • 5.1.1.4. Emerging markets showing significant interest and potential in antibiotic resistance solutions
    • 5.1.2. Restraints
      • 5.1.2.1. Regulatory hurdles and approval delays hindering the introduction of novel antibiotics
    • 5.1.3. Opportunities
      • 5.1.3.1. Development of novel antibiotics targeting antibiotic resistant bacterial strains to address critical healthcare needs
      • 5.1.3.2. Implementation of advanced diagnostic tools for early detection and management of antibiotic resistant infections
      • 5.1.3.3. Exploration of alternative therapies such as bacteriophages and probiotics to combat antibiotic resistance
    • 5.1.4. Challenges
      • 5.1.4.1. Lack of collaboration between pharmaceutical companies and academic institutions in antibiotic research
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Antibiotic Resistance Market, by Type

  • 6.1. Introduction
  • 6.2. Antibacterial Products
  • 6.3. Antifungal Products
  • 6.4. Antiparasitic Products
  • 6.5. Antiviral Products

7. Antibiotic Resistance Market, by Mechanism of Action

  • 7.1. Introduction
  • 7.2. Cell Wall Synthesis Inhibitors
  • 7.3. DNA Gyrase Inhibitors
  • 7.4. Protein Synthesis Inhibitors
  • 7.5. RNA Polymerase Inhibitors

8. Antibiotic Resistance Market, by Spectrum of Activity

  • 8.1. Introduction
  • 8.2. Broad-Spectrum Antibiotics
  • 8.3. Narrow-Spectrum Antibiotics

9. Antibiotic Resistance Market, by Drug Class

  • 9.1. Introduction
  • 9.2. Cephalosporins
  • 9.3. Fluoroquinolones
  • 9.4. Macrolides
  • 9.5. Penicillins
  • 9.6. Tetracyclines

10. Antibiotic Resistance Market, by Route of Administration

  • 10.1. Introduction
  • 10.2. Intravenous
  • 10.3. Oral

11. Antibiotic Resistance Market, by End User

  • 11.1. Introduction
  • 11.2. Clinics
  • 11.3. Homecare Settings
  • 11.4. Hospitals

12. Antibiotic Resistance Market, by Distribution Channel

  • 12.1. Introduction
  • 12.2. Hospital Pharmacies
  • 12.3. Online Pharmacies
  • 12.4. Retail Pharmacies

13. Americas Antibiotic Resistance Market

  • 13.1. Introduction
  • 13.2. Argentina
  • 13.3. Brazil
  • 13.4. Canada
  • 13.5. Mexico
  • 13.6. United States

14. Asia-Pacific Antibiotic Resistance Market

  • 14.1. Introduction
  • 14.2. Australia
  • 14.3. China
  • 14.4. India
  • 14.5. Indonesia
  • 14.6. Japan
  • 14.7. Malaysia
  • 14.8. Philippines
  • 14.9. Singapore
  • 14.10. South Korea
  • 14.11. Taiwan
  • 14.12. Thailand
  • 14.13. Vietnam

15. Europe, Middle East & Africa Antibiotic Resistance Market

  • 15.1. Introduction
  • 15.2. Denmark
  • 15.3. Egypt
  • 15.4. Finland
  • 15.5. France
  • 15.6. Germany
  • 15.7. Israel
  • 15.8. Italy
  • 15.9. Netherlands
  • 15.10. Nigeria
  • 15.11. Norway
  • 15.12. Poland
  • 15.13. Qatar
  • 15.14. Russia
  • 15.15. Saudi Arabia
  • 15.16. South Africa
  • 15.17. Spain
  • 15.18. Sweden
  • 15.19. Switzerland
  • 15.20. Turkey
  • 15.21. United Arab Emirates
  • 15.22. United Kingdom

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2023
  • 16.2. FPNV Positioning Matrix, 2023
  • 16.3. Competitive Scenario Analysis
  • 16.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AbbVie Inc.
  • 2. Allergan plc
  • 3. Amgen Inc.
  • 4. AstraZeneca PLC
  • 5. Aurobindo Pharma Limited
  • 6. Bayer AG
  • 7. Bristol-Myers Squibb Company
  • 8. Cipla Limited
  • 9. Eli Lilly and Company
  • 10. Gilead Sciences, Inc.
  • 11. GlaxoSmithKline plc
  • 12. Johnson & Johnson
  • 13. Merck & Co., Inc.
  • 14. Novartis AG
  • 15. Pfizer Inc.
  • 16. Roche Holding AG
  • 17. Sanofi S.A.
  • 18. Sun Pharmaceutical Industries Ltd.
  • 19. Takeda Pharmaceutical Company Limited
  • 20. Teva Pharmaceutical Industries Ltd.

LIST OF FIGURES

  • FIGURE 1. ANTIBIOTIC RESISTANCE MARKET RESEARCH PROCESS
  • FIGURE 2. ANTIBIOTIC RESISTANCE MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY MECHANISM OF ACTION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY MECHANISM OF ACTION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY SPECTRUM OF ACTIVITY, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY SPECTRUM OF ACTIVITY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY DRUG CLASS, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY DRUG CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 15. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY END USER, 2023 VS 2030 (%)
  • FIGURE 17. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 19. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. AMERICAS ANTIBIOTIC RESISTANCE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. AMERICAS ANTIBIOTIC RESISTANCE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. UNITED STATES ANTIBIOTIC RESISTANCE MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 23. UNITED STATES ANTIBIOTIC RESISTANCE MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 24. ASIA-PACIFIC ANTIBIOTIC RESISTANCE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 25. ASIA-PACIFIC ANTIBIOTIC RESISTANCE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 26. EUROPE, MIDDLE EAST & AFRICA ANTIBIOTIC RESISTANCE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 27. EUROPE, MIDDLE EAST & AFRICA ANTIBIOTIC RESISTANCE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 28. ANTIBIOTIC RESISTANCE MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 29. ANTIBIOTIC RESISTANCE MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. ANTIBIOTIC RESISTANCE MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. ANTIBIOTIC RESISTANCE MARKET DYNAMICS
  • TABLE 7. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY ANTIBACTERIAL PRODUCTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY ANTIFUNGAL PRODUCTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY ANTIPARASITIC PRODUCTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY ANTIVIRAL PRODUCTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY CELL WALL SYNTHESIS INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY DNA GYRASE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY PROTEIN SYNTHESIS INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY RNA POLYMERASE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY SPECTRUM OF ACTIVITY, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY BROAD-SPECTRUM ANTIBIOTICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY NARROW-SPECTRUM ANTIBIOTICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY CEPHALOSPORINS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY FLUOROQUINOLONES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY MACROLIDES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY PENICILLINS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY TETRACYCLINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY HOMECARE SETTINGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 35. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 36. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 37. AMERICAS ANTIBIOTIC RESISTANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 38. AMERICAS ANTIBIOTIC RESISTANCE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 39. AMERICAS ANTIBIOTIC RESISTANCE MARKET SIZE, BY SPECTRUM OF ACTIVITY, 2018-2030 (USD MILLION)
  • TABLE 40. AMERICAS ANTIBIOTIC RESISTANCE MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 41. AMERICAS ANTIBIOTIC RESISTANCE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 42. AMERICAS ANTIBIOTIC RESISTANCE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 43. AMERICAS ANTIBIOTIC RESISTANCE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 44. AMERICAS ANTIBIOTIC RESISTANCE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 45. ARGENTINA ANTIBIOTIC RESISTANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 46. ARGENTINA ANTIBIOTIC RESISTANCE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 47. ARGENTINA ANTIBIOTIC RESISTANCE MARKET SIZE, BY SPECTRUM OF ACTIVITY, 2018-2030 (USD MILLION)
  • TABLE 48. ARGENTINA ANTIBIOTIC RESISTANCE MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 49. ARGENTINA ANTIBIOTIC RESISTANCE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 50. ARGENTINA ANTIBIOTIC RESISTANCE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 51. ARGENTINA ANTIBIOTIC RESISTANCE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 52. BRAZIL ANTIBIOTIC RESISTANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 53. BRAZIL ANTIBIOTIC RESISTANCE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 54. BRAZIL ANTIBIOTIC RESISTANCE MARKET SIZE, BY SPECTRUM OF ACTIVITY, 2018-2030 (USD MILLION)
  • TABLE 55. BRAZIL ANTIBIOTIC RESISTANCE MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 56. BRAZIL ANTIBIOTIC RESISTANCE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 57. BRAZIL ANTIBIOTIC RESISTANCE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 58. BRAZIL ANTIBIOTIC RESISTANCE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 59. CANADA ANTIBIOTIC RESISTANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 60. CANADA ANTIBIOTIC RESISTANCE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 61. CANADA ANTIBIOTIC RESISTANCE MARKET SIZE, BY SPECTRUM OF ACTIVITY, 2018-2030 (USD MILLION)
  • TABLE 62. CANADA ANTIBIOTIC RESISTANCE MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 63. CANADA ANTIBIOTIC RESISTANCE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 64. CANADA ANTIBIOTIC RESISTANCE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 65. CANADA ANTIBIOTIC RESISTANCE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 66. MEXICO ANTIBIOTIC RESISTANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 67. MEXICO ANTIBIOTIC RESISTANCE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 68. MEXICO ANTIBIOTIC RESISTANCE MARKET SIZE, BY SPECTRUM OF ACTIVITY, 2018-2030 (USD MILLION)
  • TABLE 69. MEXICO ANTIBIOTIC RESISTANCE MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 70. MEXICO ANTIBIOTIC RESISTANCE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 71. MEXICO ANTIBIOTIC RESISTANCE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 72. MEXICO ANTIBIOTIC RESISTANCE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 73. UNITED STATES ANTIBIOTIC RESISTANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 74. UNITED STATES ANTIBIOTIC RESISTANCE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 75. UNITED STATES ANTIBIOTIC RESISTANCE MARKET SIZE, BY SPECTRUM OF ACTIVITY, 2018-2030 (USD MILLION)
  • TABLE 76. UNITED STATES ANTIBIOTIC RESISTANCE MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 77. UNITED STATES ANTIBIOTIC RESISTANCE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 78. UNITED STATES ANTIBIOTIC RESISTANCE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 79. UNITED STATES ANTIBIOTIC RESISTANCE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 80. UNITED STATES ANTIBIOTIC RESISTANCE MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 81. ASIA-PACIFIC ANTIBIOTIC RESISTANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 82. ASIA-PACIFIC ANTIBIOTIC RESISTANCE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 83. ASIA-PACIFIC ANTIBIOTIC RESISTANCE MARKET SIZE, BY SPECTRUM OF ACTIVITY, 2018-2030 (USD MILLION)
  • TABLE 84. ASIA-PACIFIC ANTIBIOTIC RESISTANCE MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 85. ASIA-PACIFIC ANTIBIOTIC RESISTANCE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 86. ASIA-PACIFIC ANTIBIOTIC RESISTANCE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 87. ASIA-PACIFIC ANTIBIOTIC RESISTANCE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 88. ASIA-PACIFIC ANTIBIOTIC RESISTANCE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 89. AUSTRALIA ANTIBIOTIC RESISTANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 90. AUSTRALIA ANTIBIOTIC RESISTANCE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 91. AUSTRALIA ANTIBIOTIC RESISTANCE MARKET SIZE, BY SPECTRUM OF ACTIVITY, 2018-2030 (USD MILLION)
  • TABLE 92. AUSTRALIA ANTIBIOTIC RESISTANCE MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 93. AUSTRALIA ANTIBIOTIC RESISTANCE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 94. AUSTRALIA ANTIBIOTIC RESISTANCE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 95. AUSTRALIA ANTIBIOTIC RESISTANCE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 96. CHINA ANTIBIOTIC RESISTANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 97. CHINA ANTIBIOTIC RESISTANCE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 98. CHINA ANTIBIOTIC RESISTANCE MARKET SIZE, BY SPECTRUM OF ACTIVITY, 2018-2030 (USD MILLION)
  • TABLE 99. CHINA ANTIBIOTIC RESISTANCE MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 100. CHINA ANTIBIOTIC RESISTANCE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 101. CHINA ANTIBIOTIC RESISTANCE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 102. CHINA ANTIBIOTIC RESISTANCE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 103. INDIA ANTIBIOTIC RESISTANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 104. INDIA ANTIBIOTIC RESISTANCE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 105. INDIA ANTIBIOTIC RESISTANCE MARKET SIZE, BY SPECTRUM OF ACTIVITY, 2018-2030 (USD MILLION)
  • TABLE 106. INDIA ANTIBIOTIC RESISTANCE MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 107. INDIA ANTIBIOTIC RESISTANCE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 108. INDIA ANTIBIOTIC RESISTANCE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 109. INDIA ANTIBIOTIC RESISTANCE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 110. INDONESIA ANTIBIOTIC RESISTANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 111. INDONESIA ANTIBIOTIC RESISTANCE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 112. INDONESIA ANTIBIOTIC RESISTANCE MARKET SIZE, BY SPECTRUM OF ACTIVITY, 2018-2030 (USD MILLION)
  • TABLE 113. INDONESIA ANTIBIOTIC RESISTANCE MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 114. INDONESIA ANTIBIOTIC RESISTANCE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 115. INDONESIA ANTIBIOTIC RESISTANCE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 116. INDONESIA ANTIBIOTIC RESISTANCE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 117. JAPAN ANTIBIOTIC RESISTANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 118. JAPAN ANTIBIOTIC RESISTANCE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 119. JAPAN ANTIBIOTIC RESISTANCE MARKET SIZE, BY SPECTRUM OF ACTIVITY, 2018-2030 (USD MILLION)
  • TABLE 120. JAPAN ANTIBIOTIC RESISTANCE MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 121. JAPAN ANTIBIOTIC RESISTANCE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 122. JAPAN ANTIBIOTIC RESISTANCE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 123. JAPAN ANTIBIOTIC RESISTANCE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 124. MALAYSIA ANTIBIOTIC RESISTANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 125. MALAYSIA ANTIBIOTIC RESISTANCE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 126. MALAYSIA ANTIBIOTIC RESISTANCE MARKET SIZE, BY SPECTRUM OF ACTIVITY, 2018-2030 (USD MILLION)
  • TABLE 127. MALAYSIA ANTIBIOTIC RESISTANCE MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 128. MALAYSIA ANTIBIOTIC RESISTANCE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 129. MALAYSIA ANTIBIOTIC RESISTANCE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 130. MALAYSIA ANTIBIOTIC RESISTANCE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 131. PHILIPPINES ANTIBIOTIC RESISTANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 132. PHILIPPINES ANTIBIOTIC RESISTANCE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 133. PHILIPPINES ANTIBIOTIC RESISTANCE MARKET SIZE, BY SPECTRUM OF ACTIVITY, 2018-2030 (USD MILLION)
  • TABLE 134. PHILIPPINES ANTIBIOTIC RESISTANCE MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 135. PHILIPPINES ANTIBIOTIC RESISTANCE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 136. PHILIPPINES ANTIBIOTIC RESISTANCE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 137. PHILIPPINES ANTIBIOTIC RESISTANCE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 138. SINGAPORE ANTIBIOTIC RESISTANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 139. SINGAPORE ANTIBIOTIC RESISTANCE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 140. SINGAPORE ANTIBIOTIC RESISTANCE MARKET SIZE, BY SPECTRUM OF ACTIVITY, 2018-2030 (USD MILLION)
  • TABLE 141. SINGAPORE ANTIBIOTIC RESISTANCE MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 142. SINGAPORE ANTIBIOTIC RESISTANCE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 143. SINGAPORE ANTIBIOTIC RESISTANCE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 144. SINGAPORE ANTIBIOTIC RESISTANCE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 145. SOUTH KOREA ANTIBIOTIC RESISTANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 146. SOUTH KOREA ANTIBIOTIC RESISTANCE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 147. SOUTH KOREA ANTIBIOTIC RESISTANCE MARKET SIZE, BY SPECTRUM OF ACTIVITY, 2018-2030 (USD MILLION)
  • TABLE 148. SOUTH KOREA ANTIBIOTIC RESISTANCE MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 149. SOUTH KOREA ANTIBIOTIC RESISTANCE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 150. SOUTH KOREA ANTIBIOTIC RESISTANCE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 151. SOUTH KOREA ANTIBIOTIC RESISTANCE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 152. TAIWAN ANTIBIOTIC RESISTANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 153. TAIWAN ANTIBIOTIC RESISTANCE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 154. TAIWAN ANTIBIOTIC RESISTANCE MARKET SIZE, BY SPECTRUM OF ACTIVITY, 2018-2030 (USD MILLION)
  • TABLE 155. TAIWAN ANTIBIOTIC RESISTANCE MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 156. TAIWAN ANTIBIOTIC RESISTANCE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 157. TAIWAN ANTIBIOTIC RESISTANCE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 158. TAIWAN ANTIBIOTIC RESISTANCE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 159. THAILAND ANTIBIOTIC RESISTANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 160. THAILAND ANTIBIOTIC RESISTANCE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 161. THAILAND ANTIBIOTIC RESISTANCE MARKET SIZE, BY SPECTRUM OF ACTIVITY, 2018-2030 (USD MILLION)
  • TABLE 162. THAILAND ANTIBIOTIC RESISTANCE MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 163. THAILAND ANTIBIOTIC RESISTANCE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 164. THAILAND ANTIBIOTIC RESISTANCE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 165. THAILAND ANTIBIOTIC RESISTANCE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 166. VIETNAM ANTIBIOTIC RESISTANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 167. VIETNAM ANTIBIOTIC RESISTANCE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 168. VIETNAM ANTIBIOTIC RESISTANCE MARKET SIZE, BY SPECTRUM OF ACTIVITY, 2018-2030 (USD MILLION)
  • TABLE 169. VIETNAM ANTIBIOTIC RESISTANCE MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 170. VIETNAM ANTIBIOTIC RESISTANCE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 171. VIETNAM ANTIBIOTIC RESISTANCE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 172. VIETNAM ANTIBIOTIC RESISTANCE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 173. EUROPE, MIDDLE EAST & AFRICA ANTIBIOTIC RESISTANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 174. EUROPE, MIDDLE EAST & AFRICA ANTIBIOTIC RESISTANCE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 175. EUROPE, MIDDLE EAST & AFRICA ANTIBIOTIC RESISTANCE MARKET SIZE, BY SPECTRUM OF ACTIVITY, 2018-2030 (USD MILLION)
  • TABLE 176. EUROPE, MIDDLE EAST & AFRICA ANTIBIOTIC RESISTANCE MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 177. EUROPE, MIDDLE EAST & AFRICA ANTIBIOTIC RESISTANCE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 178. EUROPE, MIDDLE EAST & AFRICA ANTIBIOTIC RESISTANCE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 179. EUROPE, MIDDLE EAST & AFRICA ANTIBIOTIC RESISTANCE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 180. EUROPE, MIDDLE EAST & AFRICA ANTIBIOTIC RESISTANCE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 181. DENMARK ANTIBIOTIC RESISTANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 182. DENMARK ANTIBIOTIC RESISTANCE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 183. DENMARK ANTIBIOTIC RESISTANCE MARKET SIZE, BY SPECTRUM OF ACTIVITY, 2018-2030 (USD MILLION)
  • TABLE 184. DENMARK ANTIBIOTIC RESISTANCE MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 185. DENMARK ANTIBIOTIC RESISTANCE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 186. DENMARK ANTIBIOTIC RESISTANCE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 187. DENMARK ANTIBIOTIC RESISTANCE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 188. EGYPT ANTIBIOTIC RESISTANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 189. EGYPT ANTIBIOTIC RESISTANCE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 190. EGYPT ANTIBIOTIC RESISTANCE MARKET SIZE, BY SPECTRUM OF ACTIVITY, 2018-2030 (USD MILLION)
  • TABLE 191. EGYPT ANTIBIOTIC RESISTANCE MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 192. EGYPT ANTIBIOTIC RESISTANCE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 193. EGYPT ANTIBIOTIC RESISTANCE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 194. EGYPT ANTIBIOTIC RESISTANCE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 195. FINLAND ANTIBIOTIC RESISTANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 196. FINLAND ANTIBIOTIC RESISTANCE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 197. FINLAND ANTIBIOTIC RESISTANCE MARKET SIZE, BY SPECTRUM OF ACTIVITY, 2018-2030 (USD MILLION)
  • TABLE 198. FINLAND ANTIBIOTIC RESISTANCE MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 199. FINLAND ANTIBIOTIC RESISTANCE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 200. FINLAND ANTIBIOTIC RESISTANCE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 201. FINLAND ANTIBIOTIC RESISTANCE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 202. FRANCE ANTIBIOTIC RESISTANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 203. FRANCE ANTIBIOTIC RESISTANCE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 204. FRANCE ANTIBIOTIC RESISTANCE MARKET SIZE, BY SPECTRUM OF ACTIVITY, 2018-2030 (USD MILLION)
  • TABLE 205. FRANCE ANTIBIOTIC RESISTANCE MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 206. FRANCE ANTIBIOTIC RESISTANCE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 207. FRANCE ANTIBIOTIC RESISTANCE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 208. FRANCE ANTIBIOTIC RESISTANCE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 209. GERMANY ANTIBIOTIC RESISTANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 210. GERMANY ANTIBIOTIC RESISTANCE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 211. GERMANY ANTIBIOTIC RESISTANCE MARKET SIZE, BY SPECTRUM OF ACTIVITY, 2018-2030 (USD MILLION)
  • TABLE 212. GERMANY ANTIBIOTIC RESISTANCE MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 213. GERMANY ANTIBIOTIC RESISTANCE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 214. GERMANY ANTIBIOTIC RESISTANCE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 215. GERMANY ANTIBIOTIC RESISTANCE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 216. ISRAEL ANTIBIOTIC RESISTANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 217. ISRAEL ANTIBIOTIC RESISTANCE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 218. ISRAEL ANTIBIOTIC RESISTANCE MARKET SIZE, BY SPECTRUM OF ACTIVITY, 2018-2030 (USD MILLION)
  • TABLE 219. ISRAEL ANTIBIOTIC RESISTANCE MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 220. ISRAEL ANTIBIOTIC RESISTANCE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 221. ISRAEL ANTIBIOTIC RESISTANCE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 222. ISRAEL ANTIBIOTIC RESISTANCE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 223. ITALY ANTIBIOTIC RESISTANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 224. ITALY ANTIBIOTIC RESISTANCE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 225. ITALY ANTIBIOTIC RESISTANCE MARKET SIZE, BY SPECTRUM OF ACTIVITY, 2018-2030 (USD MILLION)
  • TABLE 226. ITALY ANTIBIOTIC RESISTANCE MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 227. ITALY ANTIBIOTIC RESISTANCE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 228. ITALY ANTIBIOTIC RESISTANCE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 229. ITALY ANTIBIOTIC RESISTANCE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 230. NETHERLANDS ANTIBIOTIC RESISTANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 231. NETHERLANDS ANTIBIOTIC RESISTANCE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 232. NETHERLANDS ANTIBIOTIC RESISTANCE MARKET SIZE, BY SPECTRUM OF ACTIVITY, 2018-2030 (USD MILLION)
  • TABLE 233. NETHERLANDS ANTIBIOTIC RESISTANCE MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 234. NETHERLANDS ANTIBIOTIC RESISTANCE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 235. NETHERLANDS ANTIBIOTIC RESISTANCE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 236. NETHERLANDS ANTIBIOTIC RESISTANCE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 237. NIGERIA ANTIBIOTIC RESISTANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 238. NIGERIA ANTIBIOTIC RESISTANCE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 239. NIGERIA ANTIBIOTIC RESISTANCE MARKET SIZE, BY SPECTRUM OF ACTIVITY, 2018-2030 (USD MILLION)
  • TABLE 240. NIGERIA ANTIBIOTIC RESISTANCE MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 241. NIGERIA ANTIBIOTIC RESISTANCE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 242. NIGERIA ANTIBIOTIC RESISTANCE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 243. NIGERIA ANTIBIOTIC RESISTANCE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 244. NORWAY ANTIBIOTIC RESISTANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 245. NORWAY ANTIBIOTIC RESISTANCE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 246. NORWAY ANTIBIOTIC RESISTANCE MARKET SIZE, BY SPECTRUM OF ACTIVITY, 2018-2030 (USD MILLION)
  • TABLE 247. NORWAY ANTIBIOTIC RESISTANCE MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 248. NORWAY ANTIBIOTIC RESISTANCE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 249. NORWAY ANTIBIOTIC RESISTANCE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 250. NORWAY ANTIBIOTIC RESISTANCE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 251. POLAND ANTIBIOTIC RESISTANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 252. POLAND ANTIBIOTIC RESISTANCE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 253. POLAND ANTIBIOTIC RESISTANCE MARKET SIZE, BY SPECTRUM OF ACTIVITY, 2018-2030 (USD MILLION)
  • TABLE 254. POLAND ANTIBIOTIC RESISTANCE MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 255. POLAND ANTIBIOTIC RESISTANCE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 256. POLAND ANTIBIOTIC RESISTANCE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 257. POLAND ANTIBIOTIC RESISTANCE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 258. QATAR ANTIBIOTIC RESISTANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 259. QATAR ANTIBIOTIC RESISTANCE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 260. QATAR ANTIBIOTIC RESISTANCE MARKET SIZE, BY SPECTRUM OF ACTIVITY, 2018-2030 (USD MILLION)
  • TABLE 261. QATAR ANTIBIOTIC RESISTANCE MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 262. QATAR ANTIBIOTIC RESISTANCE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 263. QATAR ANTIBIOTIC RESISTANCE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 264. QATAR ANTIBIOTIC RESISTANCE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 265. RUSSIA ANTIBIOTIC RESISTANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 266. RUSSIA ANTIBIOTIC RESISTANCE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 267. RUSSIA ANTIBIOTIC RESISTANCE MARKET SIZE, BY SPECTRUM OF ACTIVITY, 2018-2030 (USD MILLION)
  • TABLE 268. RUSSIA ANTIBIOTIC RESISTANCE MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 269. RUSSIA ANTIBIOTIC RESISTANCE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 270. RUSSIA ANTIBIOTIC RESISTANCE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 271. RUSSIA ANTIBIOTIC RESISTANCE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 272. SAUDI ARABIA ANTIBIOTIC RESISTANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 273. SAUDI ARABIA ANTIBIOTIC RESISTANCE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 274. SAUDI ARABIA ANTIBIOTIC RESISTANCE MARKET SIZE, BY SPECTRUM OF ACTIVITY, 2018-2030 (USD MILLION)
  • TABLE 275. SAUDI ARABIA ANTIBIOTIC RESISTANCE MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 276. SAUDI ARABIA ANTIBIOTIC RESISTANCE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 277. SAUDI ARABIA ANTIBIOTIC RESISTANCE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 278. SAUDI ARABIA ANTIBIOTIC RESISTANCE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 279. SOUTH AFRICA ANTIBIOTIC RESISTANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 280. SOUTH AFRICA ANTIBIOTIC RESISTANCE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 281. SOUTH AFRICA ANTIBIOTIC RESISTANCE MARKET SIZE, BY SPECTRUM OF ACTIVITY, 2018-2030 (USD MILLION)
  • TABLE 282. SOUTH AFRICA ANTIBIOTIC RESISTANCE MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 283. SOUTH AFRICA ANTIBIOTIC RESISTANCE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 284. SOUTH AFRICA ANTIBIOTIC RESISTANCE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 285. SOUTH AFRICA ANTIBIOTIC RESISTANCE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 286. SPAIN ANTIBIOTIC RESISTANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 287. SPAIN ANTIBIOTIC RESISTANCE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 288. SPAIN ANTIBIOTIC RESISTANCE MARKET SIZE, BY SPECTRUM OF ACTIVITY, 2018-2030 (USD MILLION)
  • TABLE 289. SPAIN ANTIBIOTIC RESISTANCE MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 290. SPAIN ANTIBIOTIC RESISTANCE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 291. SPAIN ANTIBIOTIC RESISTANCE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 292. SPAIN ANTIBIOTIC RESISTANCE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 293. SWEDEN ANTIBIOTIC RESISTANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 294. SWEDEN ANTIBIOTIC RESISTANCE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 295. SWEDEN ANTIBIOTIC RESISTANCE MARKET SIZE, BY SPECTRUM OF ACTIVITY, 2018-2030 (USD MILLION)
  • TABLE 296. SWEDEN ANTIBIOTIC RESISTANCE MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 297. SWEDEN ANTIBIOTIC RESISTANCE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 298. SWEDEN ANTIBIOTIC RESISTANCE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 299. SWEDEN ANTIBIOTIC RESISTANCE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 300. SWITZERLAND ANTIBIOTIC RESISTANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 301. SWITZERLAND ANTIBIOTIC RESISTANCE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 302. SWITZERLAND ANTIBIOTIC RESISTANCE MARKET SIZE, BY SPECTRUM OF ACTIVITY, 2018-2030 (USD MILLION)
  • TABLE 303. SWITZERLAND ANTIBIOTIC RESISTANCE MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 304. SWITZERLAND ANTIBIOTIC RESISTANCE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 305. SWITZERLAND ANTIBIOTIC RESISTANCE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 306. SWITZERLAND ANTIBIOTIC RESISTANCE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 307. TURKEY ANTIBIOTIC RESISTANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 308. TURKEY ANTIBIOTIC RESISTANCE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 309. TURKEY ANTIBIOTIC RESISTANCE MARKET SIZE, BY SPECTRUM OF ACTIVITY, 2018-2030 (USD MILLION)
  • TABLE 310. TURKEY ANTIBIOTIC RESISTANCE MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 311. TURKEY ANTIBIOTIC RESISTANCE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 312. TURKEY ANTIBIOTIC RESISTANCE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 313. TURKEY ANTIBIOTIC RESISTANCE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 314. UNITED ARAB EMIRATES ANTIBIOTIC RESISTANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 315. UNITED ARAB EMIRATES ANTIBIOTIC RESISTANCE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 316. UNITED ARAB EMIRATES ANTIBIOTIC RESISTANCE MARKET SIZE, BY SPECTRUM OF ACTIVITY, 2018-2030 (USD MILLION)
  • TABLE 317. UNITED ARAB EMIRATES ANTIBIOTIC RESISTANCE MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 318. UNITED ARAB EMIRATES ANTIBIOTIC RESISTANCE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 319. UNITED ARAB EMIRATES ANTIBIOTIC RESISTANCE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 320. UNITED ARAB EMIRATES ANTIBIOTIC RESISTANCE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 321. UNITED KINGDOM ANTIBIOTIC RESISTANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 322. UNITED KINGDOM ANTIBIOTIC RESISTANCE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 323. UNITED KINGDOM ANTIBIOTIC RESISTANCE MARKET SIZE, BY SPECTRUM OF ACTIVITY, 2018-2030 (USD MILLION)
  • TABLE 324. UNITED KINGDOM ANTIBIOTIC RESISTANCE MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 325. UNITED KINGDOM ANTIBIOTIC RESISTANCE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 326. UNITED KINGDOM ANTIBIOTIC RESISTANCE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 327. UNITED KINGDOM ANTIBIOTIC RESISTANCE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 328. ANTIBIOTIC RESISTANCE MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 329. ANTIBIOTIC RESISTANCE MARKET, FPNV POSITIONING MATRIX, 2023